retatrutide phase 2 trial results weight loss Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Retatrutide, an experimental weight-loss drug,

Purinergic system, in 7th Edn.edsSiegelG

Theranostics 10, 53985411

Collectively, these data show that GLP-1RA/tesaglitazar outperforms the GLP-1RA and tesaglitazar to decrease body weight and to improve glucose metabolism in mice with genetically induced obesity and glucose intolerance

Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP4-inhibitors

The 200 mcg twice-daily protocol delivers 400 mcg total daily exposure and is typically used in initial dose-finding studies or when stacking with other GH secretagogues

The proposed model outperforms the traditional machine learning methods on all four metrics